PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study
- PMID: 29846031
- DOI: 10.1002/ejhf.1213
PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study
Abstract
We report the rationale and design of a community PHARMacy-based prospective randomized controlled interdisciplinary study for ambulatory patients with Chronic Heart Failure (PHARM-CHF) and results of its pilot study. The pilot study randomized 50 patients to a pharmacy-based intervention or usual care for 12 months. It demonstrated the feasibility of the design and showed reduced systolic blood pressure in the intervention group as indicator for improved medication adherence. The main study will randomize patients ≥60 years on stable pharmacotherapy including at least one diuretic and a history of heart failure hospitalization within 12 months. The intervention group will receive a medication review at baseline followed by regular dose dispensing of the medication, counselling regarding medication use and symptoms of heart failure. The control patients are unknown to the pharmacy and receive usual care. The primary efficacy endpoint is medication adherence, pre-specified as a significant difference of the proportion of days covered between the intervention and control group within 365 days following randomization using pharmacy claims data for three CHF medications (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists). The primary composite safety endpoint is days lost due to blindly adjudicated unplanned cardiovascular hospitalizations or death. Overall, 248 patients shall be randomized. The minimum follow-up is 12 months with an expected mean of 24 months. Based on the feasibility demonstrated in the pilot study, the randomized PHARM-CHF trial will test whether an interdisciplinary pharmacy-based intervention can safely improve medication adherence and will estimate the potential impact on clinical endpoints. ClinicalTrials.gov Identifier: NCT01692119.
Keywords: Chronic heart failure; Community pharmacy services; Hospitalization; Interdisciplinary care; Medication adherence; Randomized controlled trial.
© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.
Comment in
-
Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means.Eur J Heart Fail. 2018 Sep;20(9):1360-1362. doi: 10.1002/ejhf.1242. Epub 2018 Jun 13. Eur J Heart Fail. 2018. PMID: 29896931 No abstract available.
-
Letter on 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial'.Eur J Heart Fail. 2020 Mar;22(3):565. doi: 10.1002/ejhf.1602. Epub 2019 Sep 9. Eur J Heart Fail. 2020. PMID: 31497909 No abstract available.
-
Letter on 'Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial': reply.Eur J Heart Fail. 2020 Mar;22(3):565-566. doi: 10.1002/ejhf.1613. Epub 2019 Sep 16. Eur J Heart Fail. 2020. PMID: 31523887 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
